PMOS Rename Highlights Diagnostic Delays and New Therapeutic Targets
The official renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) in May 2026 aims to better reflect the condition's systemic nature. While the diagnostic criteria remain unchanged, the new name acknowledges that ovarian cysts are not a requirement for diagnosis. This shift highlights significant diagnostic delays, with many patients waiting years for confirmation, and underscores the need for treatments addressing insulin resistance and metabolic issues rather than just symptom masking.












